Axsome Therapeutics Inc (NASDAQ: AXSM) has reported a loss for its second fiscal quarter (ending June 30) of $-1.67 versus a loss $-1.54 for the same period a year ago. This result fell short of the consensus estimate of $-1.33 by $-0.34. For the latest four quarters through June 30, E.P.S. were $-6.51 versus $-4.28 for the same period a year ago.
Recent Price Action
Axsome Therapeutics Inc (NASDAQ: AXSM) stock declined modestly by -1.4% on 8/5/24. The stock closed at $83.21. NORMAL trading volume accompanied the decline. The stock has been strong relative to the market over the last nine months but has declined -3.8% during the last week.
Current PriceTarget Research Rating
AXSM is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Axsome Therapeutics has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Axsome Therapeutics has a very low Appreciation Score of 4 but a slightly positive Power Rating of 69, resulting in the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment